Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
(9h)
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
(11h)
J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
(14h)
AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
(15h)
Spruce spins out preclinical endocrinology program into newly formed Adrenyx
(15h)
BioPharma Dive
BIO unveils plan for US to remain biotech’s ‘global leader’
(1h)
Bayer wins FDA nod for a new kind of blood thinner
(7h)
Vir hepatitis D drug succeeds in first pivotal study
(13h)
Argenx to buy peptide platform in potentially billion-dollar deal
(13h)
Ramaswamy’s biotech baggage haunted his political run
(14h)
Endpoints News
Bayer wins FDA approval for stroke prevention drug Sunharbo
(6h)
How early efforts to build autonomous clinical AI tools are approaching regulation
(9h)
Trump’s drug pricing deals force tough choices on launches
(10h)
FDA orders GLP-1 drugmakers to warn of rare eye disease
(10h)
US government removes WuXi AppTec from Chinese military list
(11h)
BioSpace
BioSpace 2027 Best Places to Work shines light on most admired employers
(1h)
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
(11h)
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
(11h)
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
(12h)
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
(12h)
STAT News
Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
(5h)
FDA approves novel Bayer drug to reduce recurrence of stroke
(7h)
Trump administration removes WuXi AppTec from its Chinese military list
(9h)
Bill Ackman’s bold plan to transform brain research
(11h)
Hospitals win the midterms, and Chopping Very Strategically
(12h)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(10h)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(5d)
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes
(5d)
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers
(2w)
Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows
(4w)
Drug Channels
BlinkRx Insights: Clarifying the Mystery around “DTP”
(3d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(4d)
Drug Channels Outlook 2027: Adam’s Final Webinar
(6d)
Biopharma’s AI Fork in the Road
(1w)
"How Do I Know I'm Not Just Giving Money Away?" The Question Every Market Access Leader Is Asking
(1w)
European Biotechnology Magazine
Immunocore doubles up on T-cell engagers in eye cancer
(13h)
argenx buys macrocycle partner Unnatural Products for up to $1.15 billion
(22h)
CDMO: How to find a reliable partner
(1d)
When genetic medicine enters the inner ear
(1d)
Turn bioprocess data into timely, transferable process control
(3d)
Drug Hunter
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(14h)
Lenacapavir, a First-in-Class HIV Capsid Inhibitor for the Treatment and Prevention of HIV-1 Infection
(15h)
Chronic CRFR2 Agonism for Muscle-Sparing Weight Loss
(3d)
RG6182
(4d)
A Deep Dive into INN Proposed List 135 Part 2 (M–Z)
(5d)
Labiotech.EU
Zooming out from ovaries: how has renaming PMOS changed lives?
(3d)
How to turn a BIO-Europe meeting into a lasting partnership
(3d)
From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026
(5d)
The biggest biotech funding rounds in October 2026
(5d)
Top biotech deals in October 2026
(6d)
Bio IT World
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(23m)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(3d)
Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences
(5d)
Quantifying the Average Human Genome
(1w)
Regulatory Affairs Is the Connective Tissue Pharma’s AI Strategy Is Missing
(2w)
GEN News
Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research
(6h)
How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome
(9h)
Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests
(16h)
New AI Models Are Turbo-Charging Protein Design
(16h)
Therapeutic Immune Manipulation
(16h)
Cure Today
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
(8h)
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
(10h)
Rural Lung Cancer: Only 36% of Medicare Patients Had Gene Testing
(14h)
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
(16h)
Nearly Half of Cancer Survivors Report Recent Alcohol Use
(2d)
Contract Pharma
Spruce Bio Spins CAH Program Off into New Subsidiary Adrenyx
(8h)
Pluri CDMO Business Adds Two ISO Certifications
(14h)
Charles River to Acquire Frontage’s Bioanalysis, DPMK Businesses
(15h)
Pierre Fabre, XtalPi Partner to Advance AI-Driven Drug Discovery
(15h)
Centrix Appoints Nathalie Huther as SVP, Business Development & Commercial
(16h)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1mo)
Study highlights advance in influenza protection for older adults
(1mo)
Medcity News
Startup Supporting Caregivers Raises $3.5M in Seed Funding
(6h)
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
(8h)
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
(8h)
Simulation-Guided Clinical Trials: Is EU Law Ready?
(15h)
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
(18h)
Chemical & Engineering News
Comment: To NOBCChE, community is everything
(5h)
Chemistry in Pictures: Golden tears
(10h)
Mitsui Chemicals will acquire JSR in electronic materials push
(11h)
Purple bacteria transform waste into valuable antioxidant
(13h)
ACS expands public policy fellowships
(14h)
The Pharma Letter
Pierre Fabre and XtalPi ink discovery AI-driven collaboration
(13h)
Adneuris files cebranopadol NDA for acute pain, pitching lower abuse potential than oxycodone
(13h)
Almirall nine-month sales up 8.3% as Ebglyss surges 75% and EBITDA climbs 22.7%
(16h)
Russia to sharply increase production of human papillomavirus vaccines
(16h)
Avanzanite builds EU commercial operation by securing Zemcelpro rights
(17h)
Targeted Oncology
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
(8h)
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
(10h)
Dr Iyer on Digitizing NCCN Guidelines for AI at the Point of Care
(11h)
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
(13h)
Benzopyran-Based Small Molecule Granted FDA Orphan Drug Status in AML
(14h)
MedWatch
Ambu board seeks sharp increase in executive bonus caps
(17h)
Demant goes on offensive with US veterans: “We aim to steadily expand our position”
(17h)
Trustee to seek disqualification of former Audientes management
(19h)
Sandoz launches Ozempic copy in Brazil
(20h)
Wegovy improves liver markers in MASH patients without obesity
(21h)
In The Pipeline
Jon Clardy, 1943-2026
(9h)
Antimicrobial Peptides for Fun (?) and Profit (?)
(4d)
The Morning After the Midterms
(5d)
Taming Photochemistry
(6d)
Chemotherapy Actually Helps Immunotherapy in Cancer
(1w)
Pharmaphorum
Amazon puts $100m into global health drive
(16h)
MHRA grants Innovation Passports to three novel drugs
(17h)
argenx agrees Unnatural takeover deal worth up to $1.15bn
(18h)
Moderna to relocate its UK HQ to London's Tribeca
(19h)
Novartis' pelacarsen fail raises questions for other drugs
(20h)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(1w)
Why we need to rethink childhood cancer treatments
(1w)
Q3 UK biotech VC heads for record year thanks to megadeals
(1w)
Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers
(1w)
New webinar: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
HIT Consultant
AWS Launches $100M Health Impact Initiative to Scale Agentic and Cloud Tech in Underserved Global Care
(13h)
M&A: XRHealth Acquires PursueCare to Bridge Immersive VR Therapy with FDA-Authorized Prescription Digital Therapeutics
(14h)
Reclaiming $44.9B in Hospital Uncompensated Care via Automated Upfront Eligibility
(15h)
CLEAR Launches Epic Toolbox Integrations for EpicCare Link and DEA-Compliant EPCS
(16h)
SEARHC Joins Mayo Clinic Care Network to Bridge Specialist Tele-Informatics Across Southeast Alaska
(16h)
Insights: Pink Sheet
US FDA Defines Risk-Based Potency Approach To Cell and Gene Therapy
(2h)
Korea Streamlines Review Of Digital Convergence Combos
(3h)
US FDA Probes Tumor Risk With Novartis’ Zolgensma And Itvisma After Gene Integration Reports
(5h)
GLP-1 Class Warning On Rare Eye Condition Driven By US FDA Meta-Analysis, Sentinel Study
(6h)
EU Risks ‘Completely Screwing Up’ Pharma Sandboxes, Academic Warns
(16h)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(2d)
Standardization, not customization: A site-CRO perspective on trial quality
(8h)
Survey finds women are willing to join trials, yet rarely invited
(11h)
Argenx buys into macrocyclic peptides with $1.15bn UNP deal
(15h)
Pharma urged to build pricing resilience
(15h)
BioCentury
China’s first-in-class deals grow as U.S. investment curbs loom — a BioCentury podcast
(3d)
Post-election pricing outlook: stormy with a chance of compromise
(3d)
Rezera proposes IPO terms amid volatile NASDAQ conditions: Public Equity Report
(3d)
Brinsupri, Rasonque extend biotech's launch momentum
(3d)
SITC 2026: Engineering immune responses inside tumors
(4d)
SCRIP
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
(1h)
Novartis’s Detailed Pelacarsen Data Leave Little Hope For Other Lp(a)-Lowering Drugs
(7h)
ACR 2026: A Tale Of Three Cell Therapies
(8h)
Argenx Buys Unnatural Products, Gaining Macrocyclic Peptide Discovery Platform
(8h)
BIO-Europe: Wise Words From Industry Vets Levin And Moses
(14h)